Trial Profile
Clinical factors associated with continued benefit after immune-related adverse events in patients treated with nivolumab for advanced malignancies
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Jul 2017
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- 05 Jul 2017 New trial record
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology